Medpace (NASDAQ:MEDP) Posts Earnings Results, Beats Expectations By $0.27 EPS

Medpace (NASDAQ:MEDP) posted its earnings results on Wednesday. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27, FiscalAI reports. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 earnings per share. Medpace updated its FY 2026 guidance to 17.250-17.950 EPS.

Medpace Trading Down 0.7%

Shares of Medpace stock opened at $528.12 on Thursday. Medpace has a 12 month low of $373.00 and a 12 month high of $628.92. The firm has a market capitalization of $15.08 billion, a P/E ratio of 33.19, a P/E/G ratio of 2.66 and a beta of 1.15. The business has a fifty day simple moving average of $484.63 and a two-hundred day simple moving average of $493.49.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Barclays dropped their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Robert W. Baird restated a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Royal Bank Of Canada reduced their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $473.09.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently bought and sold shares of MEDP. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Quarry LP bought a new stake in shares of Medpace in the 3rd quarter worth approximately $35,000. Greenline Wealth Management LLC bought a new stake in shares of Medpace in the 4th quarter worth approximately $55,000. Group One Trading LLC grew its stake in shares of Medpace by 120.0% in the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after buying an additional 600 shares during the last quarter. Finally, Johnson Financial Group Inc. grew its stake in shares of Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after buying an additional 59 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.